Travere Therapeutics (TVTX): Evaluating Valuation After Strong Share Price Rally
Travere Therapeutics (TVTX) has attracted interest lately, thanks to a series of strong returns. The stock has climbed 67% over the past year and more than 56% in the past 3 months, outpacing many of its biotech peers.
See our latest analysis for Travere Therapeutics.
Momentum has clearly been building for Travere Therapeutics, with the recent 1-month share price return of nearly 18% adding to a strong 1-year total shareholder return of over 67%. Even after such a big run, the current share price suggests some investors see further upside or perhaps have renewed confidence in the pipeline and management’s strategy.
If Travere’s rally has you looking for the next big mover in life sciences, you can uncover more promising companies…
